Six of our polyclonals in kidney cancer research

January 2023 (the Clinical Proteomic Tumor Analysis Consortium, USA).

This study enhances our understanding of kidney cancer, a complex and heterogeneous disease, by utilizing various analytical approaches.

Li Y, et al. Clinical Proteomic Tumor Analysis Consortium.
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. Cancer Cell. 2023 Jan 9;41(1):139-163.e17.

Clear cell renal cell carcinoma (ccRCC) is a kidney cancer and a complex disease defined by a histopathologic feature that has demonstrated variability and heterogeneity through the increased use of diverse analytic methodologies.

Building on previous evidence, this study enhances our understanding of this complex and heterogeneous disease by utilizing various analytical approaches such as:

1) an enhanced histopathologic review,

2) proteogenomic and single-nuclei analysis of multi-sampled tumors,

3) in vitro analysis of therapeutically targeted tumor-specific phosphoproteomic events,

4) tumor metabolomics and

5) the first analysis of tumor-specific glycoprotein signatures.

The results of the study should facilitate clinical translation, including elucidation of prospective patient outcome-dependent signatures and therapeutic targets to aid in personalized treatment of ccRCC patients.

👉 Read the full article:

👉 This study used 6 TripleA Polyclonals from Atlas Antibodies:
anti-HYOU1 (HPA049296)
anti-GAL3ST1 (HPA001220)
anti-KIF2A (HPA004716)
anti-PLXDC2 (HPA017268)
anti-TGFBI (HPA008612)
anti-UCHL1 (HPA005993)

🌏 Our antibodies are used worldwide!

Read more about our antibodies in action 🌏